The REVIVED-BCIS2 trial: percutaneous coronary intervention vs. optimal medical therapy for stable patients with severe ischaemic cardiomyopathy

Rocco Vergallo¹, Giovanna Liuzzo^{1

2}

Affiliations

¹ Department of Cardiovascular Medicine, Interventional Cardiology Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo A. Gemelli, 8-00168, Rome, Italy.
² Catholic University of the Sacred Heart, Largo F. Vito, 8, 00168, Rome, Italy.

Comment

Rocco Vergallo et al. Eur Heart J. 2022.

. 2022 Dec 7;43(46):4775-4776.

doi: 10.1093/eurheartj/ehac568.

Rocco Vergallo¹, Giovanna Liuzzo^{1

2}

¹ Department of Cardiovascular Medicine, Interventional Cardiology Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo A. Gemelli, 8-00168, Rome, Italy.
² Catholic University of the Sacred Heart, Largo F. Vito, 8, 00168, Rome, Italy.

No abstract available

Conflict of interest statement

Conflict of interest: R.V. received speaker's fees from Abbott Vascular and Terumo. Other author declared no conflict of interest.

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, Morgan HP, Dodd M, Evans R, Canter R, Arnold S, Dixon LJ, Edwards RJ, De Silva K, Spratt JC, Conway D, Cotton J, McEntegart M, Chiribiri A, Saramago P, Gershlick A, Shah AM, Clark AL, Petrie MC; REVIVED-BCIS2 Investigators. Perera D, et al. N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027563 Clinical Trial.